Zai Lab Acquires Global Rights to UCB Inflammatory Disease Drug

Zai Lab, a two-year old Shanghai biotech, has in-licensed global rights from UCB, the Belgium multinational, to a first-in-class monoclonal antibody aimed at treating autoimmune and other inflammatory diseases. According to Zai, the candidate is ready for IND enabling studies and will probably start a clinical Phase I trial in 2016. The initial indications appear to be graft-versus-host disease and inflammatory bowel disease. So far, Zai has in-licensed four molecules, all of them close to clinical stage. More details.... Stock Symbol: (Euronext: UCB) Share this with colleagues: // //